Report: Meningococcal vaccines market to be propelled by inclusive vaccination schedules

9th June 2016 (Last Updated June 9th, 2016 18:30)

The market for meningococcal vaccines is projected to expand at a compound annual growth rate of 5.4% to reach $1.8bn in value by 2025, according to a recent report by GlobalData.

The market for meningococcal vaccines is projected to expand at a compound annual growth rate of 5.4% to reach $1.8bn in value by 2025, according to a recent report by GlobalData. Meningococcal vaccines market will witness a growth from the estimated $1.1bn in 2015, across eight major markets including the US, France, Germany, Italy, Spain, the UK, Japan and Brazil.

Titled 'PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2025', the report states that the market expansion will be a result of a change in the national immunisation schedules. Authorities are taking steps to prevent invasive meningococcal disease by introducing more inclusive schedules into the national infant and adolescent vaccination schedules.

A new vaccine covering all serogroups is also expected to be introduced, which will positively impact the meningococcal vaccines market. The first-in-class vaccine will be developed by combining two different meningococcal vaccines, leading to a reduction in dosage burden.

The GlobalData analysis highlights that although a large number of vaccines are available in the market, they provide protection against a specific serogroup or a set of serogroups. There is a huge opportunity in the market to launch a single vaccine covering all prevalent serogroups and, therefore, reducing the number of vaccinations required to combat meningococcal.

"GlobalData expects that GSK will pass Sanofi as the main provider of meningococcal vaccines by the end of this forecast period."

The meningococcal vaccines market is currently influenced by several key players including Big Pharma, Sanofi, GlaxoSmithKline (GSK), Pfizer and Novartis. The market place has witnessed several changes recently with Novartis selling its meningococcal vaccine portfolio to GSK, as well as the entry of GSK's Bexsero and Pfizer's Trumenba, the only vaccinations offering protection against serogroup B.

Multiple factors, such as a mature meningococcal vaccine market and decreasing meningococcal disease incidence rates, are predicted to be the main obstacles in the launch of new products.

Ph.D. GlobalData's infectious diseases analyst Mirco Junker, says: "GlobalData expects that GSK will pass Sanofi as the main provider of meningococcal vaccines by the end of this forecast period.

"This growth in the company's market share will be driven by Bexsero, which will hit sales of more than $570m in 2025, as well as their novel pentavalent vaccine, MenABCWY, which is expected to launch in the US and five European countries during the forecast period."